Cabozantinib Tablets and Fedratinib Hydrochloride
Determining the interaction of Cabozantinib Tablets and Fedratinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with cabozantinib is associated with severe, sometimes fatal hemorrhage including hemoptysis and gastrointestinal hemorrhage. In clinical trials, the incidence of Grade 3 hemorrhagic events was higher in patients receiving cabozantinib compared with placebo (3% vs. 1%). MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. References "Product Information. Cometriq (cabozantinib)." Exelixis Inc, S San Francisco, CA.
Professional:MONITOR CLOSELY: Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with cabozantinib is associated with severe, sometimes fatal hemorrhage including hemoptysis and gastrointestinal hemorrhage. In clinical trials, the incidence of Grade 3 hemorrhagic events was higher in patients receiving cabozantinib compared with placebo (3% vs. 1%).
MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
- "Product Information. Cometriq (cabozantinib)." Exelixis Inc, S San Francisco, CA.
Generic Name: cabozantinib
Brand name: Cabometyx, Cometriq
Synonyms: Cabozantinib
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cabozantinib Tablets-Feiba
- Cabozantinib Tablets-Feiba NF
- Cabozantinib Tablets-Feiba VH Immuno
- Cabozantinib Tablets-Feiba-VH
- Cabozantinib Tablets-Felbamate
- Cabozantinib Tablets-Felbamate Oral Suspension
- Fedratinib Hydrochloride-Caduet
- Fedratinib Hydrochloride-Cafcit
- Fedratinib Hydrochloride-Cafcit (Caffeine Citrate Injection Solution)
- Fedratinib Hydrochloride-Cafcit (Caffeine Citrate Oral Solution)
- Fedratinib Hydrochloride-Cafcit Intravenous
- Fedratinib Hydrochloride-Cafcit Oral